Be Biopharma Launches with $52 Million Series A Financing to Advance B Cells as Medicines
Amount Raised
$52 Million
Round Type
Series A
CambridgeInformation TechnologyBiotechnologySoftwareData And AnalyticsScience And EngineeringDescription
Be Biopharma (“Be Bio”), a leader in developing B cells as medicines, founded by Longwood Fund, David Rawlings, MD, and Richard James, PhD, today announced a $52 million Series A financing led by Atlas Venture and RA Capital Management and joined by Alta Partners, Longwood Fund and Takeda Ventures, Inc. The company plans to use this funding to precisely engineer B cells to treat a range of diseases, building on the pioneering work of Drs. Rawlings and James at Seattle Children’s Research Institute. B cells are prolific protein producers that can be collected from peripheral blood, have a programmable lifetime that could last decades, can target specific tissues, and have broad, customizable functionality.
Quick answer
Be Biopharma raised $52 Million in a Series A round, dated October 22, 2020. Be Biopharma is based in Cambridge, Massachusetts, United States.
- How much did Be Biopharma raise?
- Be Biopharma raised $52 Million in a Series A round on October 22, 2020.
- What does Be Biopharma do?
- Be Biopharma (“Be Bio”) is pioneering Engineered B Cell Medicines (BCMs) to dramatically improve the lives of patients who are living with Hemophilia B and other genetic diseases, cancer, and other serious conditions.
- Where is Be Biopharma based and how big is it?
- Be Biopharma is based in Cambridge, Massachusetts, United States.
- Who are the decision-makers at Be Biopharma?
- Fundz holds 1 contact at Be Biopharma. Names and contact details are shown to Fundz members.
Source: Fundz verified event record.
Who else raised in Data And Analytics and Science And Engineering around the same time
Companies in the same sectors as Be Biopharma that raised within 45 days of this round, from Fundz verified event records.
- SentinelOne, Inc. raised $267M (Series F) on November 11, 2020.
- Unlearn raised an undisclosed amount (Series A) on November 5, 2020.
- Deci raised $9M (Seed) on October 27, 2020.
- DYNAMO METRICS, INC. raised $460K (Seed) on October 23, 2020.
- Clarity AI raised $23M on October 9, 2020.
- Aidoc raised $47M (Series B) on September 16, 2020.
Who to call at Be Biopharma, and when
A new round usually means Be Biopharma is about to hire and buy. The teams that reach out first get the meeting.
- An alert the day Be Biopharma raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Be Biopharma, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Be Biopharma. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Be Biopharma raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Funding Insights
What this usually meansBe Biopharma raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.